We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

GeneGo Licenses MetaCore Data Analysis Suite to AVEO Pharmaceuticals

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

GeneGo, Inc. has announced that they have licensed their MetaCore Data Mining Suite to AVEO Pharmaceuticals. The latest version, MetaCore 4.5, includes GeneGo disease enrichment and functional ontology.

MetaCore has an in depth knowledge base for human diseases and the ability to concurrently visualize gene expression, proteomics, genetic and metabolic data. The suite's data management system is designed for automated upload and handling of hundreds to thousands of genome-wide files, which makes MetaCore a robust OMICs repository platform of choice. MetaCore is used in both research and clinical groups in drug development.

"We are pleased that AVEO chose the MetaCore suite of products to enhance its analytical capabilities," says Julie Bryant, Vice President of GeneGo. "AVEO's vision and focus in cancer drug research and development is inspiring and we believe our MetaCore suite of data mining tools will be an asset to their efforts."